BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Koh XY, Koh XH, Hwang LA, Ferrer FJ, Rahmat SAB, Lama D, Lane DP. Therapeutic anti-cancer activity of antibodies targeting sulfhydryl bond constrained epitopes on unglycosylated RON receptor tyrosine kinase. Oncogene 2019;38:7342-56. [PMID: 31417186 DOI: 10.1038/s41388-019-0946-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Wang Z, Yang Y, Hu S, He J, Wu Z, Qi Z, Huang M, Liu R, Lin Y, Tan C, Xu M, Zhang Z. Short-form RON (sf-RON) enhances glucose metabolism to promote cell proliferation via activating β-catenin/SIX1 signaling pathway in gastric cancer. Cell Biol Toxicol 2021;37:35-49. [PMID: 32399910 DOI: 10.1007/s10565-020-09525-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Rodrigues JG, Duarte HO, Reis CA, Gomes J. Aberrant protein glycosylation in cancer: implications in targeted therapy. Biochem Soc Trans 2021;49:843-54. [PMID: 33704376 DOI: 10.1042/BST20200763] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Yao HP, Suthe SR, Hudson R, Wang MH. Antibody-drug conjugates targeting RON receptor tyrosine kinase as a novel strategy for treatment of triple-negative breast cancer. Drug Discov Today 2020;25:1160-73. [PMID: 32479905 DOI: 10.1016/j.drudis.2020.05.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Yao HP, Hudson R, Wang MH. RON receptor tyrosine kinase in pancreatic ductal adenocarcinoma: Pathogenic mechanism in malignancy and pharmaceutical target for therapy. Biochim Biophys Acta Rev Cancer. 2020;1873:188360. [PMID: 32234337 DOI: 10.1016/j.bbcan.2020.188360] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Diniz F, Coelho P, Duarte HO, Sarmento B, Reis CA, Gomes J. Glycans as Targets for Drug Delivery in Cancer. Cancers 2022;14:911. [DOI: 10.3390/cancers14040911] [Reference Citation Analysis]
6 Yao HP, Suthe SR, Tong XM, Wang MH. Targeting RON receptor tyrosine kinase for treatment of advanced solid cancers: antibody-drug conjugates as lead drug candidates for clinical trials. Ther Adv Med Oncol. 2020;12:1758835920920069. [PMID: 32426050 DOI: 10.1177/1758835920920069] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Yao HP, Tong XM, Hudson R, Wang MH. MET and RON receptor tyrosine kinases in colorectal adenocarcinoma: molecular features as drug targets and antibody-drug conjugates for therapy. J Exp Clin Cancer Res 2020;39:198. [PMID: 32962738 DOI: 10.1186/s13046-020-01711-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Deng P, Xiao F, Wang Z, Jin G. A Novel BODIPY Quaternary Ammonium Salt-Based Fluorescent Probe: Synthesis, Physical Properties, and Live-Cell Imaging. Front Chem 2021;9:650006. [PMID: 33777904 DOI: 10.3389/fchem.2021.650006] [Reference Citation Analysis]